Total Neoadjuvant Therapy in Rectal Cancer Treatment

• Status: Recruiting
• Trial end date: 2023-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized, controlled, parallel study to determine the efficiency and safety of total neoadjuvant therapy in rectal cancer treatment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: State Scientific Centre of Coloproctology, Russian Federation

Criteria

Inclusion Criteria:

• Have signed an approved informed consent form for the stud;

• Histologically confirmed rectal adenocarcinoma low (cT2-4N0-2M0) or mid rectum (сТ2-T4N1-2M0);

Exclusion Criteria:

• rectal cancer recurrence;

• Primary-multiple tumours of other localizations;

• pelvis radiotherapy in anamnesis;

• pregnancy, breastfeeding;

• distant metastasis;

• ECOG score 3-4